• Aucun résultat trouvé

ASMF SUBMISSION FORM: ADMINISTRATIVE DATAregarding an European Active Substance Master File (ASMF) ANSM -

N/A
N/A
Protected

Academic year: 2022

Partager "ASMF SUBMISSION FORM: ADMINISTRATIVE DATAregarding an European Active Substance Master File (ASMF) ANSM -"

Copied!
1
0
0

Texte intégral

(1)

ANSM - Agence nationale de sécurité du médicament et des produits de santé

Formulaire – MED590

Contact ANSM

DMFR – MPF – 530

143-147, bd Anatole France F-93285 SAINT-DENIS CEDEX

ASMF SUBMISSION FORM: ADMINISTRATIVE DATA regarding an European Active Substance Master File (ASMF)

ASMF Number as allocated by ANSM (if available):

Date of Submission Letter:

Active Substance : Name: Manufacturer Internal Code:

ASMF Holder :

Name

Contact person at following address

Address Country

Type of submission :

New submission

Update to ASMF

Total (submission of a complete file superseding the previous version) Partial (submission of a complementary file modifying the previous version)

Compilation (submission of a compilation of the previous version including responses to different deficiency letters)

Response to Deficiency Letter along with the copy of the Deficiency Letter

Administrative change

Change of ASMF Holder

Change of Name/Address of ASMF Holder

Change of Name/Address of Active Substance Manufacturer

Request for closing of ASMF along with Withdrawal of Access Letter(s)

Replacement by a Certificate of Suitability (CEP) : CEP Number : Module 3- Applicants Part: version number

(Name ASMF Holder/Name Active Substance/AP/version number/date in yyyy-mm-dd)

Module 3- Restricted Part: version number

(Name ASMF Holder/Name Active Substance/RP/version number/date in yyyy-mm-dd)

Module 1- Information about the Expert : Name of the Expert’s:

 Enclose a copy of the Submission Letter and Administrative Details for documents relating to an Active Substance Master File (ASMF) (Annex 3 of the European Guideline on Active Substance Master File Procedure

CHMP/QWP/227/02 Rev 3 – adopted on 21 June 2012) including:

Table of changes (for Update of ASMF)

Copy of Deficiency Letter (for Response to Deficiency Letter)

 Enclose letter(s) of withdrawal of Access Letter (for Request for Closing of ASMF)

To be filled in by Ansm Date : Signature :

Complete Submission for assessment

Submission to be completed for assessment (see reasons in annex A)

ANSM Version 1 – (Février / 2014) www.ansm.sante.fr 1 / 1

Références

Documents relatifs

 We wish to make an integrated model which is able to evaluate in a single computation cycle all the relevant aspects of the design being studied:..  Elastic and

PALLIER LEOPOLDINE 1994 SENIOR C.S.. QUINTIN THOMAS 1984

· A partir de la 12 ème semaine d’aménorrhée et jusqu’à la naissance, tous les AINS, par l’inhibition de la synthèse des prostaglandines, peuvent exposer le fœtus à

(Received 11 July 2019; revised manuscript received 8 October 2019; published 4 December 2019) We reduce a one-dimensional model of an active segment (AS), which is used, for

Pour un contrôle optimal de l’infestation par les puces et les tiques, le médicament vétérinaire doit être administré à intervalles de 12 semaines.. En cas de traitement des

En l’absence de données disponibles, l’utilisation de ce médicament vétérinaire chez les chiots âgés de moins de 8 semaines et/ou chez des chiens dont le poids est inférieur

On 23 February 2018, the European Commission (EC) was informed on the cases of seven patients treated with daclizumab beta in 2016 and 2017 who have experienced after initiation

crude PL models are evident. In 2003, Ireland appears alone at the top of the plot. This matches the cluster structure returned by the PL model in which Ireland appears alone.